

**REMARKS**

Claims 1-11 are currently pending in this application. By way of this Reply, claims 7-11 have been added. Applicants submit that no new matter has been added by way of this amendment.

The Examiner has taken the position that the claims are drawn to the following distinct inventions pursuant to 35 U.S.C. §§ 121 and 372:

**Group I:** claim 1 drawn to a medicament, comprising a recombinant poxvirus; and


**Group II:** claims 2-6, drawn to a detection method of an interaction of the chemokine-binding molecule with chemokine in the sample.

In response to this restriction requirement, Applicants elect the invention of Group I for prosecution on the merits. Applicants submit that the invention of Group I corresponds to claim 1 as noted in the Restriction Requirement as well as newly added claims 7-11.

Prompt examination of claims 1 and 7-11 is respectfully requested.

Respectfully submitted,

Smith et al.

By   
Ryan W. O'Donnell  
Registration No. 53,401  
(215) 568-6400

Volpe and Koenig, P.C.  
United Plaza, Suite 1600  
30 South 17th Street  
Philadelphia, PA 19103

RWO/vs  
Enclosure